Business Context and Reporting Period
Company: NewAmsterdam Pharma Company N.V.
Filing Type: Form 8-K (Current Report)
Date of Report: February 18, 2026
Reporting Period: The filing announces corporate updates and financial results for the year ended December 31, 2025.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) for detailed results. The filing text itself does not provide specific numerical values for the following metrics:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It only indicates that such results were announced in a press release furnished as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on February 18, 2026, containing corporate updates and full-year 2025 financial results.
Legal Status of Information: The information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" under the Exchange Act. It is not subject to Section 18 liability and will not be incorporated by reference into other filings unless expressly stated.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 18, 2026) for actual revenue, profit, and cash flow figures for the year ended December 31, 2025.
- Verify the specific "corporate updates" mentioned in the press release to understand operational changes.
- Confirm whether the furnished financial data includes any restatements or adjustments to prior periods.
- Check subsequent filings for any incorporation of the furnished data into formal financial statements.